ACIU — AC Immune SA Income Statement
0.000.00%
Last trade - 00:00
- $237.08m
- $127.13m
- CH₣14.80m
- 36
- 22
- 64
- 35
C2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 110 | 15.4 | 0 | 3.94 | 14.8 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 65.9 | 76.7 | 79 | 74.8 | 68.4 |
Operating Profit | 44.5 | -61.3 | -79 | -70.8 | -53.6 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 45.4 | -61.9 | -73 | -70.7 | -54.2 |
Provision for Income Taxes | |||||
Net Income After Taxes | 45.4 | -61.9 | -73 | -70.8 | -54.2 |
Net Income Before Extraordinary Items | |||||
Net Income | 45.4 | -61.9 | -73 | -70.8 | -54.2 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 45.4 | -61.9 | -73 | -70.8 | -54.2 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.639 | -0.861 | -0.974 | -0.847 | -0.64 |